Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 27 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 9358287

    Method of treating stress hyperglycemia with human antibodies to the glucagon receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 7, 2016 · Expires Jun 2, 2036

    granted
  2. US 9353176

    Method of treating osteoarthritis with an antibody to NGF

    REGENERON PHARMACEUTICALS, INC. · Granted May 31, 2016 · Expires May 26, 2036

    granted
  3. US 9353163

    Apelin fusion proteins and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted May 31, 2016 · Expires May 26, 2036

    granted
  4. US 9340594

    VEGF antagonist formulations for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted May 17, 2016 · Expires May 12, 2036

    granted
  5. US 9308256

    Method of treating rheumatoid arthritis with an anti-IL-6R antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 12, 2016 · Expires Apr 7, 2036

    granted
  6. US 9309326

    Readily isolated bispecific antibodies with native immunoglobulin format

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 12, 2016 · Expires Apr 7, 2036

    granted
  7. US 9302015

    Anti-PRLR antibodies and methods for killing PRLR-expressing cells

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted
  8. US 9301509

    Genetically modified mice and engraftment

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 5, 2016 · Expires Mar 31, 2036

    granted
  9. US 9290574

    Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 22, 2016 · Expires Mar 17, 2036

    granted
  10. US 9284380

    Anti-ErbB3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 15, 2016 · Expires Mar 10, 2036

    granted
  11. US 9273143

    Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Mar 1, 2016 · Expires Feb 25, 2036

    granted
  12. US 9265827

    Anti-PDGFR-beta antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 23, 2016 · Expires Feb 18, 2036

    granted
  13. US 9260515

    Antibodies to human GDF8

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 16, 2016 · Expires Feb 11, 2036

    granted
  14. US 9254338

    Use of a VEGF antagonist to treat angiogenic eye disorders

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 9, 2016 · Expires Feb 4, 2036

    granted
  15. US 9238692

    Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 19, 2016 · Expires Jan 14, 2036

    granted
  16. US 9228014

    Antibodies capable of blocking the interaction between CD48 and a CD48 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 5, 2016 · Expires Dec 31, 2035

    granted
  17. US 9193977

    Non-human animals having a humanized signal-regulatory protein gene

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 24, 2015 · Expires Nov 19, 2035

    granted
  18. US 9193801

    Stabilized formulations containing anti-PCSK9 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 24, 2015 · Expires Nov 19, 2035

    granted
  19. US 9173880

    Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 3, 2015 · Expires Oct 29, 2035

    granted
  20. US 9150648

    Anti-ASIC1 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 6, 2015 · Expires Oct 1, 2035

    granted
  21. US 9139644

    Modified chimeric polypeptides with improved pharmacokinetic properties

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 22, 2015 · Expires Sep 17, 2035

    granted
  22. US 9132192

    Anti-EGFR antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 15, 2015 · Expires Sep 10, 2035

    granted
  23. US 9127292

    Non-human animals having a humanized signal-regulatory protein gene

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 8, 2015 · Expires Sep 3, 2035

    granted
  24. US 9127068

    Nucleic acids encoding human glucagon receptor antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Sep 8, 2015 · Expires Sep 3, 2035

    granted